Cargando…

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer

The landscape of advanced prostate cancer treatment has evolved tremendously in past decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) alone to doublet combinations comprising ADT with docetaxel or an androgen receptor inhibitor, and now triplet therapy involving al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Kenneth, Kostos, Louise, Azad, Arun A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Topic Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415497/ https://www.ncbi.nlm.nih.gov/pubmed/36029329 http://dx.doi.org/10.1007/s00345-022-04135-8

Ejemplares similares

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
por: Kostos, Louise, et al.
Publicado: (2023)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
por: Yanagisawa, Takafumi, et al.
Publicado: (2022)

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
por: Schoots, Ivo G., et al.
Publicado: (2019)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

MRI as a screening tool for prostate cancer: current evidence and future challenges
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

Ablation energies for focal treatment of prostate cancer
por: Lodeizen, Olivia, et al.
Publicado: (2018)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature
por: Le Guevelou, Jennifer, et al.
Publicado: (2023)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
por: Kohli, Manish, et al.
Publicado: (2020)

Modern paradigms for prostate cancer detection and management
por: Williams, Isabella SC, et al.
Publicado: (2022)

Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment
por: Roth, Rebecca, et al.
Publicado: (2020)

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
por: Fettke, Heidi, et al.
Publicado: (2023)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Overdiagnosis and overtreatment of early detected prostate cancer
por: Bangma, C. H., et al.
Publicado: (2007)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
por: Schoots, Ivo G., et al.
Publicado: (2019)

The present and future burden of urinary bladder cancer in the world
por: Ploeg, Martine, et al.
Publicado: (2009)

Novel contrast-enhanced ultrasound imaging in prostate cancer
por: Smeenge, Martijn, et al.
Publicado: (2011)

Androgen receptor footprint on the way to prostate cancer progression
por: Hodgson, Myles C., et al.
Publicado: (2011)

Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2020)

Keloids and Hypertrophic Scars: Update and Future Directions
por: Huang, Chenyu, et al.
Publicado: (2013)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score
por: Taha, Heba F., et al.
Publicado: (2022)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
por: Mori, Keiichiro, et al.
Publicado: (2021)

Follow-up in non-muscle invasive bladder cancer: facts and future
por: Witjes, J. Alfred
Publicado: (2020)

Spirituality and end-of-life care in disadvantaged men dying of prostate cancer
por: Bergman, Jonathan, et al.
Publicado: (2010)

The ‘C’ Words: parallels and analogies between Prostate Cancer and Covid-19
por: Klotz, Laurence, et al.
Publicado: (2021)

The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate
por: Mamoulakis, Charalampos, et al.
Publicado: (2010)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Do prostate cancer-related mobile phone apps have a role in contemporary prostate cancer management? A systematic review by EAU young academic urologists (YAU) urotechnology group
por: Jamnadass, Enakshee, et al.
Publicado: (2020)

AlphaBet: Combination of Radium-223 and [(17)(7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
por: Kostos, Louise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vgmlf5l7iu25p7eiv201j3h8k9